ADVFN Logo ADVFN

No pudimos encontrar ningún resultado para:
Asegúrate de que la ortografía sea correcta o intenta ampliar tu búsqueda.

Tendencias Ahora

Listas Principales

Parece que no has iniciado sesión.
Haz clic en el botón de abajo para iniciar sesión y ver tu historial reciente.

Hot Features

Registration Strip Icon for alerts Regístrate para obtener alertas en tiempo real, cartera personalizada y movimientos del mercado.

COCP Cocrystal Pharma Inc

2.25
-0.11 (-4.66%)
31 May 2024 - Cerrado
Retrasado por 15 minutos
Nombre de la Acción Símbolo de la Acción Bolsa de Valores Tipo de Valor
Cocrystal Pharma Inc COCP NASDAQ Acción Común
  Variación del Día (ptos.) Variación del Día (%) Último Precio Hora
-0.11 -4.66% 2.25 19:00:00
Precio de Apertura Precio Mínimo Precio Máximo Precio de cierre Precio Anterior
2.32 2.23 2.3371 2.25 2.36
más cotizaciones de acciones »

Noticias Recientes

Fecha Hora Fuente Noticia
13/5/202407:15EDGAR2Form 8-K - Current report
13/5/202407:00EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
13/5/202407:00GLOBECocrystal Pharma Reports First Quarter 2024 Financial..
07/5/202415:30EDGAR2Form DEF 14A - Other definitive proxy statements
01/5/202407:00GLOBEEnrollment Completed in Phase 2a Study with Cocrystal..
28/3/202407:00GLOBECocrystal Pharma Reports 2023 Financial Results and Provides..
19/3/202407:00GLOBECocrystal Pharma Receives Pre-IND Responses from the FDA on..
01/3/202415:15EDGAR2Form 8-K - Current report
08/1/202407:00EDGAR2Form 8-K - Current report
04/1/202415:01EDGAR2Form 8-K - Current report
04/1/202407:00GLOBECocrystal Pharma Provides an Update on the Clinical..
02/1/202408:53EDGAR2Form SC 13G/A - Statement of acquisition of beneficial..
21/12/202316:00EDGAR2Form 8-K - Current report
06/12/202307:00EDGAR2Form 8-K - Current report
06/12/202307:00GLOBECocrystal Pharma Announces First-Patient-In for Phase 2a..
04/12/202307:00EDGAR2Form 8-K - Current report
29/11/202307:00EDGAR2Form 8-K - Current report
29/11/202307:00GLOBECocrystal Pharma Highlights its Novel Inhaled and Oral..
27/11/202307:00GLOBECocrystal Pharma to Present at the NobleCon 19 Conference on..
13/11/202307:15EDGAR2Form 8-K - Current report
13/11/202307:01EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
13/11/202307:00GLOBECocrystal Pharma Reports Third Quarter 2023 Financial..
09/11/202307:00GLOBECocrystal Pharma to Discuss Progress with Novel Inhaled and..
31/10/202307:00EDGAR2Form 8-K - Current report
31/10/202307:00GLOBECocrystal Pharma Receives UK MHRA Authorization to Initiate..
28/9/202307:00GLOBECocrystal Pharma Doses First Subjects in Clinical Study of..
05/9/202307:00GLOBECocrystal Pharma to Participate in the H.C. Wainwright..
16/8/202315:05EDGAR2Form 8-K - Current report
14/8/202307:00EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
14/8/202307:00GLOBECocrystal Pharma Reports Second Quarter 2023 Financial..
08/8/202307:00GLOBECocrystal Pharma Selects Novel Oral Protease Inhibitor..
20/7/202315:05EDGAR2Form 4 - Statement of changes in beneficial ownership of..
20/7/202315:05EDGAR2Form 4 - Statement of changes in beneficial ownership of..
20/7/202315:05EDGAR2Form 4 - Statement of changes in beneficial ownership of..
20/7/202315:05EDGAR2Form 4 - Statement of changes in beneficial ownership of..